Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS 77 Return-on-Tangible-Equity is 15.23% as of Dec. 2025, which is 4% below its 10-year median of 15.82. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 1,199 Biotechnology companies, Arterra Bioscience SpA ranks better than 90.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Arterra Bioscience SpA's annualized net income for the quarter that ended in Dec. 2025 was €1.84 Mil. Arterra Bioscience SpA's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €12.10 Mil. Therefore, Arterra Bioscience SpA's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 15.23%.
The historical rank and industry rank for Arterra Bioscience SpA's Return-on-Tangible-Equity or its related term are showing as below:
MIL:ARBS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.26 Med: 15.82 Max: 50.43
Current: 16.92
During the past 9 years, Arterra Bioscience SpA's highest Return-on-Tangible-Equity was 50.43%. The lowest was 10.26%. And the median was 15.82%.
MIL:ARBS's Return-on-Tangible-Equity is ranked better than 90.24% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs MIL:ARBS: 16.92
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Arterra Bioscience SpA Return-on-Tangible-Equity Related Terms
Arterra Bioscience SpA Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.23% mean?
Arterra Bioscience SpA (MIL:ARBS) has a Return-on-Tangible-Equity of 15.23% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Arterra Bioscience SpA and its competitors. This is near median its historical median of 15.82. Over the past decade, Arterra Bioscience SpA's Return-on-Tangible-Equity has ranged from 10.26 to 50.43. According to the industry distribution chart, Arterra Bioscience SpA ranks #117 out of 1199 companies in the Biotechnology industry, placing it in the top 9.8%.
Is Arterra Bioscience SpA's Return-on-Tangible-Equity too high?
Arterra Bioscience SpA's current Return-on-Tangible-Equity of 15.23% is near median its 10-year median of 15.82. Over the past 10 years, this metric has ranged from a low of 10.26 to a high of 50.43. Based on the distribution chart, Arterra Bioscience SpA ranks #117 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #117 out of 1199 companies for Return-on-Tangible-Equity. This places Arterra Bioscience SpA in the top 10% of its industry — outperforming the majority of peers. Historically, Arterra Bioscience SpA's own Return-on-Tangible-Equity has ranged from 10.26 to 50.43 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Arterra Bioscience SpA and its competitors. Arterra Bioscience SpA's current Return-on-Tangible-Equity is 15.23%, which is near median its own 10-year median of 15.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current Return-on-Tangible-Equity is 15.23%, which is near median its 10-year median of 15.82. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Return-on-Tangible-Equity is 15.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Return-on-Tangible-Equity: 15.23% (near median its 10-year median of 15.82)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
